Target intelligence / Profile preview

Immunoglobulin heavy chain variable region third complementarity-determining region (CDR-H3)

Target
CDR-H3
Molecular classification
Antibody region, Complementarity-determining region, Hypervariable loop
01

Overview

The immunoglobulin heavy chain variable region third complementarity-determining region (CDR-H3, HCDR3) is a highly diverse polypeptide segment within the variable domain of the heavy chain of antibodies. It is formed by V(D)J recombination, incorporating sequence from variable (V), diversity (D), and joining (J) gene segments, with additional junctional diversity generated during B cell development[2][3][1]. CDR-H3 constitutes the central part of the antibody's antigen-binding site, and it is the most diverse region among all six antibody CDRs. This diversity underlies the enormous antigen recognition potential of the adaptive immune system, making CDR-H3 critical for the specificity and affinity of antibody-antigen binding[3][7][1]. In biomedical research and diagnostics, the sequence and length of heavy chain CDR3 regions serve as molecular fingerprints for B cell clonality and immune repertoire profiling, such as in lymphoma diagnostics or neutralizing antibody studies[4][6]. Summary: This entry refers to a functionally critical region of antibodies, not a discrete molecular target such as a receptor or enzyme, and should not be considered a canonical therapeutic target. The proper context for CDR-H3 is as a sequence feature within immunoglobulins, essential for antigen recognition, immune diversity, and as a molecular biomarker in immune profiling, but not itself an actionable therapeutic target.

Other names
CDR3 of heavy chainheavy chain CDR3HCDR3Ig heavy chain CDR3third complementarity-determining region of immunoglobulin heavy chain
02

Biological functions

Antigen recognitionDetermination of antibody specificityGeneration of immune diversity
03

Disease associations

Other (e.g., biomarker of clonal expansion in autoimmune disease[6]; can relate to malignancy clonality, as in lymphoid neoplasms)
04

Biomarkers

B cell clonality (in disease diagnostics, e.g., leukemia, lymphoma, autoimmune diseases[6])Adaptive immune response tracking (immune repertoire analysis, vaccine monitoring[4])

Beyond the preview

Go deeper on Immunoglobulin heavy chain variable region third complementarity-determining region (CDR-H3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Immunoglobulin heavy chain variable region third complementarity-determining region (CDR-H3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call